Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Cost of RevenueEBIATGross ProfitShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Exousia Bio (LMMY) Cost of Revenue (2024 - 2025)

Lamy (LMMY) has disclosed Cost of Revenue for 2 consecutive years, with $1317.0 as the latest value for Q4 2025.

  • Quarterly Cost of Revenue changed N/A to $1317.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8568.0 through Nov 2025, down 32.36% year-over-year, with the annual reading at $7251.0 for FY2025, 24.99% down from the prior year.
  • Cost of Revenue hit $1317.0 in Q4 2025 for Lamy, down from $7251.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $9667.0 in Q2 2024 to a low of $1317.0 in Q4 2025.